TRAX (First Tracks Biotherapeutics) EBIT: $ Mil (TTM As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics EBIT?

First Tracks Biotherapeutics TRAX +11.85% 12 EBIT is $ Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was $-181.10 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. First Tracks Biotherapeutics's annualized ROC % for the quarter that ended in Dec. 2024 was -319.89%. First Tracks Biotherapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -1,049.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

First Tracks Biotherapeutics  (NAS:TRAX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

First Tracks Biotherapeutics's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-181.101 * ( 1 - 0% )/( (51.924 + 61.302)/ 2 )
=-181.101/56.613
=-319.89 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=444.109 - 11.853 - ( 390.904 - max(0, 18.223 - 398.555+390.904))
=51.924

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=441.891 - 26.839 - ( 385.373 - max(0, 36.183 - 389.933+385.373))
=61.302

Note: The Operating Income data used here is one times the annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

First Tracks Biotherapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-181.101/( ( (18.272 + max(-8.795, 0)) + (16.232 + max(-29.698, 0)) )/ 2 )
=-181.101/( ( 18.272 + 16.232 )/ 2 )
=-181.101/17.252
=-1,049.74 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.651) - (11.853 + 0 + 4.593)
=-8.795

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.56) - (26.839 + 0 + 7.419)
=-29.698

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

First Tracks Biotherapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=/978.045
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EBIT Related Terms

First Tracks Biotherapeutics EBIT Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EBIT Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
EBIT
-118.46 -181.10

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
EBIT -118.46 -181.10

TRAX vs ALT, RGNX, MDXG: EBIT Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's EV-to-EBIT falls into.


TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
First Tracks Biotherapeutics (TRAX) has a EBIT of $ Mil as of Dec. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on First Tracks Biotherapeutics.
Is First Tracks Biotherapeutics' EBIT too high?
First Tracks Biotherapeutics' current EBIT is $ Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' EBIT compare to ALT and RGNX?
First Tracks Biotherapeutics' EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on First Tracks Biotherapeutics. First Tracks Biotherapeutics's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current EBIT of $ Mil. The current EBIT is $ Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current EBIT is $ Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price